Mahamaya Lifesciences IPO Listing at 2% premium at ₹116 Per Share

Click and Sign Up to Get Latest Updates on Mahamaya Lifesciences Limited

Mahamaya Lifesciences IPO Listing:

On the BSE platform, shares are listed at ₹116 per share, reflecting a premium of 1.75% against the issue price of 114 per share. On the other hand, on the SME platform, shares are listed at ₹116.5 per share, reflecting a premium of 2%.

Mahamaya Lifesciences IPO Subscription Status

The Mahamaya Lifesciences IPO was subscribed 1.63 times at the close of the bidding. In this subscription, qualified institutional buyers (QIBs) received 1.19 times the allocation, and non-institutional investors (NIIs) received 3.63 times the allocation. The retail quota of the issue was subscribed to 33.33%. 

Mahamaya Lifesciences IPO: Check Key Details

It is a book-building issue of 2,900 crore shares. The issue is entirely a fresh issue of 9.88 crore shares. And an offer for sale of 3.48 crore shares. The IPO is expected to be listed on the BSE and NSE with a tentative listing date of 18th November 2025. The Mahamaya Lifesciences IPO is expected to take place from 11th November 2025 to 13th November 2025. The face value of Mahamaya Lifesciences IPO shares is ₹1 per share, and the IPO price is set at ₹108 to ₹114 per share.

About Mahamaya Lifesciences Limited

Mahamaya Lifesciences Limited was established in 2007 and is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts for crop & soil health management, aiming to enhance productivity in the farming community. The company specialises in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs). The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).

• Experienced management team consisting of experts.
• Capability to introduce vital products for Indian Agriculture.
• Development of export opportunities for products.
• Ability to develop brands.
• Cordial relationships with suppliers of raw materials.

Mahamaya Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Mahamaya Lifesciences Limited’s IPO. Refer to the table to learn about Mahamaya Lifesciences Limited’s financial information. 

Explanation

Mahamaya Lifesciences Limited’s revenue increased by 64% from ₹162.83 crore in March 2024 to ₹267.17 crore in March 2025. Moreover, the company’s PAT increased by 148% from ₹5.22 crores to ₹12.94 crores. Investors can analyse other relevant factors and make a decision accordingly.

Mahamaya Lifesciences IPO Objectives

The primary objective of the Mahamaya Lifesciences IPO is to raise ₹2,900.00 crore. However, before applying for the IPO, it is essential to be aware of its secondary objectives. Explore them below

• Purchase of Equipment for the existing Formulation plant
• Funding capital expenditure towards setting up a new technical manufacturing plant
• Construction of Warehouse Building and Purchase of Machinery
• Funding the working capital requirement of our Company
• General Corporate purposes

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial  Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here